Oregon Cancer

A new study at Providence Cancer Institute tests the effectiveness of an experimental treatment and chemotherapy to inhibit tumor growth in people with lung cancer.

While tobacco is by far the leading cause of lung cancer, it's not the only contributor. Learn about other significant risk factors and what you can do to protect yourself and your loved ones.

Researchers at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in Portland, Oregon, joined leading cancer immunotherapy professionals around the world for the largest

Providence Cancer Institute breast cancer experts are researching new treatments for women with triple-negative breast cancer and HER-2 positive breast cancer.

Experts in biomedical engineering, immunology and surgical oncology are working collaboratively to improve outcomes for people with head, neck and other cancers.

Providence Cancer Institute to open new clinical study of CAR T-cell therapy to people with clear cell renal cell carcinoma, the most common type of kidney cancer.

First-in-human immune therapy study at Providence Cancer Institute will assess the safety and effectiveness of talquetamab as a potential treatment for cancerous plasma cells known as multiple myeloma

Providence researchers awarded funding from National Cancer Institute to study “Bugs as Drugs.”

Providence Cancer Institute’s Rectal Cancer Program among the first 25 in the nation to earn accreditation from the National Accreditation Program for Rectal Cancer.

Providence Cancer Institute to offer a new phase I/II study of a first-in-class photoimmunotherapy for solid tumors that overexpress the epidermal growth factor receptor protein.

Researchers at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute, will join oncology professionals around the world for the 2021 ASCO Annual Virtual Conference.

Providence Cancer Institute to offer phase II clinical trial of neoadjuvant chemotherapy plus immunotherapy for patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

A phase II, investigator-initiated clinical trial at Providence Cancer Institute aims to improve survival for patients with triple-negative breast cancer. The trial is available only at Providence.

Learn about a potential immune benefit for infants from lactating mothers who have received a COVID-19 vaccine.

New clinical trial at Providence Cancer Institute combining targeted therapy with checkpoint immunotherapy for patients with metastatic thyroid cancer.

Michael Kelley Endowed Chair for Cancer Research awarded to Providence Cancer Institute radiation oncologist, Dr. Marka Crittenden.

Attendees will have an opportunity to connect with experts in the immunotherapy field at the live virtual event held on Thursday, April 8, 2021.

Three new studies at Providence Cancer Institute will investigate the benefits of adjuvant immunotherapy for patients with completely resected melanoma who are at high risk of recurrence.

Providence Cancer Institute is the only center in the Pacific Northwest to offer a groundbreaking study of adoptive T-cell therapy ADP-A2M4 in combination with the checkpoint inhibitor pembrolizumab.